Page 151 - Read Online

Zacharakis et al. Hepatoma Res 2018;4:65 I http://dx.doi.org/10.20517/2394-5079.2018.76 Page 13 of 15

53. Beyoğlu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, et al. Tissue metabolomics of hepatocellular carcinoma: tumor
energy metabolism and the role of transcriptomic classification. Hepatology 2013;58:229-38.
54. Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, et al. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis
through GC/MS and UPLC/MS-MS. Liver Int 2014;34:1428-44.
55. Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell
Proteomics 2013;12:846-55.
56. Chen K, Shi W, Xin Z, Wang H, Zhu X, et al. Replication of genome wide association studies on hepatocellular carcinoma susceptibility
loci in a chinese population. PLoS One 2013; doi: 10.1371/journal.pone.0077315.
57. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a
serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
58. Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-
analysis. J Cancer Res Clin Oncol 2013;139:1417-24.
59. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular
carcinoma. J Hepatol 2012;56:167-75.
60. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of
HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207.
61. Osada T, Sakamoto M, Nagawa H, Yamamoto J, Matsuno Y, et al. Acquisition of glutamine synthetase expression in human
hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Cancer 1999;85:819-31.
62. Feng J, Zhu R, Chang C, Yu L, Cao F, et al. CK19 and glypican 3 expression profiling in the prognostic indication for patients with HCC
after surgical resection. PLoS One 2016; doi: 10.1371/journal.pone.0151501.
63. Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, et al. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: a meta-analysis. Clin
Chim Acta 2015;448:161-9.
64. Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, et al. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other
liver cancers. World J Gastroenterol 2012;18:4751-7.
65. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for
hepatocellular carcinoma. J Hepatol 2005;43:1007-12.
66. Tian L, Wang Y, Xu D, Gui J, Jia X, et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J
Cancer 2011;129:1923-31.
67. Xu WJ, Guo BL, Han YG, Shi L, Ma WS. Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with
low AFP levels. Tumor Biol 2014;35:12069-74.
68. Qin L. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med 2014;8:24-32.
69. Ramchandani D, Weber GF. Interactions between osteopontin and vascular endothelial growth factor: implications for cancer. Biochim
Biophys Acta 2015;1855:202-22.
70. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma.
Hepatology 2012;55:483-90.
71. Weber GF. The cancer biomarker osteopontin: combination with other markers. Cancer Genomics and Proteomics 2011;8:263-88.
72. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, et al. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular
carcinoma. Int J Cancer 2005;116:579-83.
73. Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, et al. Diagnostic and prognostic role of SCCA-IgM serum levels in
hepatocellular carcinoma (HCC). J Gastroenterol Hepatol 2014;29:1637-44.
74. Lokman NA, Ween MP, Oehler MK, Ricciardelli C. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron
2011;4:199-208.
75. Sun Y, Gao G, Cai J, Wang Y, Qu X, et al. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma.
Carcinogenesis 2013;34:595-604.
76. Fu LL, Wen X, Bao JK, Liu B. MicroRNA-modulated autophagic signaling networks in cancer. Int J Biochem Cell Biol 2012;44:733-6.
77. Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res 2015;45:128-41.
78. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J
Hepatol 2012;56:1371-83.
79. Chen X, Zhang Q, Ma W, Lan T, Hong Z, et al. The abnormal expression of microRNA-542-3p in hepatocellular carcinoma and its clinical
significance. Dis Markers 2018; doi: 10.1155/2018/3973250.
80. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular
carcinoma by down-regulating rho-kinase 2. Gastroenterology 2011;140:322-31.
81. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, et al. MicroRNA profile predicts recurrence after resection in patients with
hepatocellular carcinoma within the Milan criteria. PLoS One 2011; doi: 10.1371/journal.pone.0016435.
82. Mei Y, You Y, Xia J, Gong JP, Wang YB. Identifying differentially expressed microRNAs between cirrhotic and non-cirrhotic hepatocellular
carcinoma and exploring their functions using bioinformatic analysis. Cell Physiol Biochem 2018;48:1443-56.
83. Wang H, Liang L, Dong Q, Huan L, He J, et al. Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by
regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma. Theranostics 2018;8:2814-29.
84. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, et al. The transcriptional landscape of the mammalian genome. Science
2005;309:1559-63.
85. Sun J, Bie B, Zhang S, Yang J, Li Z. Long non-coding RNAs: critical players in hepatocellular carcinoma. Int J Mol Sci 2014;15:20434-48.
86. Zhu X, Wu YB, Zhou J, Kang DM. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression.
Biochem Biophys Res Commun 2016;469:319-25.